FDA approval opens way for H2 Holdings fundraising efforts
TechnologyApr 5, 2012
The U.S. Food and Drug Administration recently approved clinical trials of a Korean company’s artificial liver transplant on humans. The approval is expected to help H2 Holdings raise capital to finance research and development.U.S.-based bio-tech firm HepaHope, which will run the trials, is an affiliate of H2 Holdings, a Korea-based company founded by Dr. Park Sung-soo. Park is the majority shareholder of H2 Holdings, which holds a 10 percent stake in HepaHope. H2 Holdings held more than 17 bil